These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 24793566)

  • 1. Synthesis and biological evaluation of steroidal derivatives as selective inhibitors of AKR1B10.
    Zhang W; Wang L; Zhang L; Chen W; Chen X; Xie M; Yan G; Hu X; Xu J; Zhang J
    Steroids; 2014 Aug; 86():39-44. PubMed ID: 24793566
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design and synthesis of polyhydroxy steroids as selective inhibitors against AKR1B10 and molecular docking.
    Chen W; Chen X; Zhou S; Zhang H; Wang L; Xu J; Hu X; Yin W; Yan G; Zhang J
    Steroids; 2016 Jun; 110():1-8. PubMed ID: 26968129
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design, synthesis and evaluation of caffeic acid phenethyl ester-based inhibitors targeting a selectivity pocket in the active site of human aldo-keto reductase 1B10.
    Soda M; Hu D; Endo S; Takemura M; Li J; Wada R; Ifuku S; Zhao HT; El-Kabbani O; Ohta S; Yamamura K; Toyooka N; Hara A; Matsunaga T
    Eur J Med Chem; 2012 Feb; 48():321-9. PubMed ID: 22236472
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibitor selectivity between aldo-keto reductase superfamily members AKR1B10 and AKR1B1: role of Trp112 (Trp111).
    Zhang L; Zhang H; Zhao Y; Li Z; Chen S; Zhai J; Chen Y; Xie W; Wang Z; Li Q; Zheng X; Hu X
    FEBS Lett; 2013 Nov; 587(22):3681-6. PubMed ID: 24100137
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selectivity determinants of inhibitor binding to the tumour marker human aldose reductase-like protein (AKR1B10) discovered from molecular docking and database screening.
    Zhao HT; Soda M; Endo S; Hara A; El-Kabbani O
    Eur J Med Chem; 2010 Sep; 45(9):4354-7. PubMed ID: 20538382
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Kinetic studies of AKR1B10, human aldose reductase-like protein: endogenous substrates and inhibition by steroids.
    Endo S; Matsunaga T; Mamiya H; Ohta C; Soda M; Kitade Y; Tajima K; Zhao HT; El-Kabbani O; Hara A
    Arch Biochem Biophys; 2009 Jul; 487(1):1-9. PubMed ID: 19464995
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structural basis for the inhibition of AKR1B10 by caffeic acid phenethyl ester (CAPE).
    Zhang L; Zhang H; Zheng X; Zhao Y; Chen S; Chen Y; Zhang R; Li Q; Hu X
    ChemMedChem; 2014 Apr; 9(4):706-9. PubMed ID: 24436249
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis and structure-activity relationship of 2-phenyliminochromene derivatives as inhibitors for aldo-keto reductase (AKR) 1B10.
    Endo S; Hu D; Suyama M; Matsunaga T; Sugimoto K; Matsuya Y; El-Kabbani O; Kuwata K; Hara A; Kitade Y; Toyooka N
    Bioorg Med Chem; 2013 Nov; 21(21):6378-84. PubMed ID: 24071447
    [TBL] [Abstract][Full Text] [Related]  

  • 9. X-ray structure of the V301L aldo-keto reductase 1B10 complexed with NADP(+) and the potent aldose reductase inhibitor fidarestat: implications for inhibitor binding and selectivity.
    Ruiz FX; Cousido-Siah A; Mitschler A; Farrés J; Parés X; Podjarny A
    Chem Biol Interact; 2013 Feb; 202(1-3):178-85. PubMed ID: 23295227
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of compound selectivity of aldo-keto reductases using differential scanning fluorimetry.
    Kabir A; Endo S; Toyooka N; Fukuoka M; Kuwata K; Kamatari YO
    J Biochem; 2017 Feb; 161(2):215-222. PubMed ID: 28003428
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selective inhibition of the tumor marker aldo-keto reductase family member 1B10 by oleanolic acid.
    Takemura M; Endo S; Matsunaga T; Soda M; Zhao HT; El-Kabbani O; Tajima K; Iinuma M; Hara A
    J Nat Prod; 2011 May; 74(5):1201-6. PubMed ID: 21561086
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design, synthesis, structure-activity relationships and X-ray structural studies of novel 1-oxopyrimido[4,5-c]quinoline-2-acetic acid derivatives as selective and potent inhibitors of human aldose reductase.
    Crespo I; Giménez-Dejoz J; Porté S; Cousido-Siah A; Mitschler A; Podjarny A; Pratsinis H; Kletsas D; Parés X; Ruiz FX; Metwally K; Farrés J
    Eur J Med Chem; 2018 May; 152():160-174. PubMed ID: 29705708
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structural basis for the inhibition of AKR1B10 by the C3 brominated TTNPB derivative UVI2008.
    Ruiz FX; Crespo I; Álvarez S; Porté S; Giménez-Dejoz J; Cousido-Siah A; Mitschler A; de Lera ÁR; Parés X; Podjarny A; Farrés J
    Chem Biol Interact; 2017 Oct; 276():174-181. PubMed ID: 28161411
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selective inhibition of the tumor marker AKR1B10 by antiinflammatory N-phenylanthranilic acids and glycyrrhetic acid.
    Endo S; Matsunaga T; Soda M; Tajima K; Zhao HT; El-Kabbani O; Hara A
    Biol Pharm Bull; 2010; 33(5):886-90. PubMed ID: 20460771
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structural analysis of sulindac as an inhibitor of aldose reductase and AKR1B10.
    Cousido-Siah A; Ruiz FX; Crespo I; Porté S; Mitschler A; Parés X; Podjarny A; Farrés J
    Chem Biol Interact; 2015 Jun; 234():290-6. PubMed ID: 25532697
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neighboring group participation. Part 15. Stereoselective synthesis of some steroidal tetrahydrooxazin-2-ones, as novel presumed inhibitors of human 5alpha-reductase.
    Wölfling J; Hackler L; Mernyák E; Schneider G; Tóth I; Szécsi M; Julesz J; Sohár P; Csámpai A
    Steroids; 2004 Jul; 69(7):451-60. PubMed ID: 15246775
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design, synthesis, and biological evaluation of novel (1-thioxo-1,2,3,4-tetrahydro-β-carbolin-9-yl)acetic acids as selective inhibitors for AKR1B1.
    Minehira D; Takeda D; Urata H; Kato A; Adachi I; Wang X; Matsuya Y; Sugimoto K; Takemura M; Endo S; Matsunaga T; Hara A; Koseki J; Narukawa K; Hirono S; Toyooka N
    Bioorg Med Chem; 2012 Jan; 20(1):356-67. PubMed ID: 22104435
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design and synthesis of potent and selective aldose reductase inhibitors based on pyridylthiadiazine scaffold.
    Chen X; Yang Y; Ma B; Zhang S; He M; Gui D; Hussain S; Jing C; Zhu C; Yu Q; Liu Y
    Eur J Med Chem; 2011 May; 46(5):1536-44. PubMed ID: 21367494
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structure-activity relationships and molecular modelling of new 5-arylidene-4-thiazolidinone derivatives as aldose reductase inhibitors and potential anti-inflammatory agents.
    Maccari R; Vitale RM; Ottanà R; Rocchiccioli M; Marrazzo A; Cardile V; Graziano AC; Amodeo P; Mura U; Del Corso A
    Eur J Med Chem; 2014 Jun; 81():1-14. PubMed ID: 24819954
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of rabbit aldose reductase-like protein with 3β-hydroxysteroid dehydrogenase activity.
    Endo S; Matsunaga T; Kumada S; Fujimoto A; Ohno S; El-Kabbani O; Hu D; Toyooka N; Mano J; Tajima K; Hara A
    Arch Biochem Biophys; 2012 Nov; 527(1):23-30. PubMed ID: 22874434
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.